USES
Gamifant (emapalumab-lzsg) is administered as an intravenous (IV) infusion by a healthcare professional in a clinical setting. It is not a medication that patients administer themselves at home.
- Administration Route: Gamifant is given as an intravenous infusion only. It is supplied as a concentrated solution that must be diluted before administration.
- Infusion Rate: The infusion is typically administered over 1 hour.
- Frequency: Gamifant is usually given twice per week (every three to four days).
- Preparation: The medication is prepared by a pharmacist or healthcare professional. It involves diluting the Gamifant concentrate in 0.9% Sodium Chloride Injection, USP. The diluted solution can be placed in a syringe or an infusion bag. Specific instructions regarding the concentration range for dilution and the type of syringe/infusion bag (e.g., non-PVC polyolefin) must be followed.
- Storage of Diluted Solution: If not administered immediately, the diluted solution can be stored under refrigeration for a limited time (e.g., no more than 4 hours). It should not be frozen.
- Monitoring During Infusion: Patients are closely monitored during the infusion for any signs of infusion-related reactions, which can occur (e.g., fever, rash, chills, hypertension). If a reaction occurs, the infusion may be temporarily stopped or slowed, and appropriate medical management will be provided.
- Duration of Treatment: Treatment with Gamifant continues until the patient no longer requires therapy for HLH (e.g., remission achieved) or until a hematopoietic stem cell transplantation (HSCT) is performed.
- Concomitant Dexamethasone: Gamifant is administered concomitantly with dexamethasone, a corticosteroid. Dexamethasone treatment usually begins the day before Gamifant administration, with specific dosing guidelines.
Given the complexity of HLH and the administration of Gamifant, this treatment requires close medical supervision in a specialized healthcare environment.
WORKING
The active substance in Gamifant, emapalumab, is a monoclonal antibody. Its mechanism of action directly targets and neutralizes interferon-gamma (IFNγ), a crucial cytokine (a signaling protein) that plays a central and upstream role in the pathogenesis of HLH.
Here’s how it works:
- IFNγ Overexpression in HLH: In patients with HLH, there’s a massive and uncontrolled overexpression of IFNγ. This excessive IFNγ drives the hyperinflammatory response that characterizes HLH. It signals immune cells, particularly macrophages, to become hyperactive.
- Targeted Binding: Emapalumab is designed to specifically recognize and bind to both soluble (free-floating) and receptor-bound forms of IFNγ.
- Neutralization of Activity: By binding to IFNγ, emapalumab effectively neutralizes its activity. This prevents IFNγ from binding to its receptors on immune cells and initiating its signaling pathways.
- Inhibition of Macrophage Activation: By blocking IFNγ signaling, Gamifant inhibits the activation of macrophages and other immune cells that are central to the destructive inflammation in HLH.
- Reduction of Proinflammatory Cytokines: This blockade ultimately leads to a reduction in the downstream release of other proinflammatory cytokines, helping to calm the “cytokine storm” that causes organ damage in HLH.
In essence, Gamifant acts by cutting off a critical signal that fuels the destructive inflammation in HLH, thereby helping to control the disease’s symptoms and progression.
SIDE EFFECTS
Gamifant (emapalumab-lzsg) can cause various side effects, reflecting its impact on the immune system and the underlying disease. Close monitoring for adverse reactions is critical during treatment.
Common side effects (reported in ≥10% of patients in clinical trials):
- Infections (very common): This is the most frequently reported side effect (occurring in over half of patients, including bacterial, viral, and fungal infections). This is due to Gamifant’s immunosuppressive nature. Specific infections like cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus infections have been observed.
- Hypertension (High Blood Pressure): A significant number of patients experience elevated blood pressure.
- Infusion-Related Reactions: These are common and can include symptoms like fever (pyrexia), rash, erythema (redness), and hyperhidrosis (excessive sweating). These often occur during the first infusion.
- Pyrexia (Fever): General fever, separate from infusion reactions.
- Hypokalemia (Low Potassium Levels):
- Constipation:
- Rash:
- Abdominal pain:
- Diarrhea:
- Lymphocytosis: An increase in the number of lymphocytes (a type of white blood cell).
- Cough:
- Irritability:
- Tachycardia (Fast Heart Rate):
- Tachypnea (Rapid Breathing):
Serious side effects (occurred in a significant percentage of patients in trials, requiring immediate medical attention):
- Serious Infections: These are a major concern and can be fatal. They include sepsis, pneumonia, bacteremia, disseminated histoplasmosis (a severe fungal infection), necrotizing fasciitis, and perforated appendicitis. Patients are often placed on prophylactic medications to prevent certain infections.
- Gastrointestinal Hemorrhage (Bleeding):
- Multiple Organ Dysfunction:
- Allergic/Hypersensitivity Reactions: While infusion-related reactions are common, more severe allergic reactions are possible.
- Anemia and Thrombocytopenia: Due to the underlying HLH, blood count abnormalities (low red blood cells, low platelets) are part of the disease, but can be exacerbated or require careful management during treatment.
Due to the serious nature of HLH and the potential for severe side effects, patients receiving Gamifant require intensive monitoring for infections and other adverse reactions. Any new or worsening symptoms should be reported to the healthcare provider immediately.
WARNINGS
Gamifant (emapalumab-lzsg) carries important warnings and precautions due to its potent immunosuppressive effects and the severe nature of the disease it treats. Close monitoring and careful management are essential.
- Increased Risk of Serious Infections: Gamifant significantly increases the risk of serious, sometimes fatal, infections, including bacterial, viral, and fungal infections (e.g., tuberculosis, histoplasmosis, herpes zoster, CMV, EBV, adenovirus).
- Pre-treatment Screening: Before starting Gamifant, patients must be thoroughly evaluated for active and latent infections, including tuberculosis (TB). If there’s a risk of TB or a positive TB test, prophylactic treatment for TB should be initiated before Gamifant.
- Monitoring During Treatment: Patients must be closely monitored for signs and symptoms of infection throughout treatment. Prophylaxis for certain infections (e.g., Pneumocystis jirovecii, fungal infections, herpes zoster) may be administered.
- Increased Risk with Live Vaccines: Do NOT administer live or live attenuated vaccines to patients receiving Gamifant and for at least 4 weeks after the last dose. Gamifant can reduce the efficacy and increase the risk of infection from these vaccines.
- Infusion-Related Reactions: Infusion-related reactions (e.g., fever, rash, pyrexia, erythema) are common, particularly during the first infusion. These can be serious and may require temporary interruption of the infusion and symptomatic treatment.
- Immunogenicity: As a monoclonal antibody, there is a potential for patients to develop anti-drug antibodies (ADAs) to emapalumab. The development of ADAs may affect the efficacy or safety profile of Gamifant.
- Laboratory Monitoring: Frequent and comprehensive laboratory monitoring is essential to assess disease response (e.g., fever, platelet count, neutrophil count, ferritin, splenomegaly, coagulopathy), monitor for infections, and manage potential side effects (e.g., blood counts, liver function tests, electrolytes).
- Hepatotoxicity: Although HLH itself can affect the liver, any worsening of liver function tests during treatment should be carefully evaluated.
- Fetal Harm: Based on its mechanism of action, Gamifant may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus.
- Lactation: It is unknown if Gamifant is excreted in human milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment and for at least 4 weeks after the last dose.
Given the severity of HLH and the potent nature of Gamifant, treatment must be managed by healthcare professionals experienced in the diagnosis and treatment of HLH.
INTERACTIONS
Gamifant (emapalumab-lzsg) can interact with other medications, primarily due to its immunosuppressive effects and its impact on the immune system. Given the critical nature of HLH and its treatment, careful consideration of all concomitant medications is essential.
Key interactions include:
- Live or Live Attenuated Vaccines: Gamifant significantly increases the risk of infection when co-administered with live or live attenuated vaccines. It can also reduce the efficacy of these vaccines by suppressing the immune response. Therefore, live or live attenuated vaccines should NOT be administered to patients receiving Gamifant and for at least 4 weeks after the last dose of Gamifant. Examples of live vaccines include MMR (measles, mumps, rubella), varicella (chickenpox), rotavirus, yellow fever, and nasal influenza vaccine.
- Other Immunosuppressants: Co-administration with other immunosuppressive therapies (e.g., upadacitinib, axicabtagene ciloleucel, brexucabtagene autoleucel, various monoclonal antibodies, or certain oral immunosuppressants like ozanimod, ponesimod, siponimod) can lead to additive immunosuppressive effects, significantly increasing the risk of serious infections. These combinations are generally contraindicated or should be avoided or used with extreme caution and close monitoring.
- Cytochrome P450 (CYP450) Substrates: Chronic inflammation, like that seen in HLH, can suppress the activity of CYP450 enzymes in the liver, which are responsible for metabolizing many drugs. By neutralizing IFNγ, Gamifant may normalize CYP450 activities. This could potentially increase the metabolism of drugs that are CYP450 substrates, leading to a reduced efficacy of these co-administered drugs. Examples of CYP450 substrates include certain antidepressants, anticonvulsants, blood thinners, and other medications. Upon initiation or discontinuation of Gamifant, monitor for reduced efficacy and adjust the dosage of CYP450 substrates as needed.
Always provide your healthcare team with a complete list of all medications, supplements, and herbal products you are taking to ensure safe and effective treatment.
DOSAGE
The dosage of Gamifant (emapalumab-lzsg) is individualized based on the patient’s actual body weight, clinical response, and laboratory parameters. It is administered as an intravenous infusion.
- Recommended Starting Dose: The recommended starting dose of Gamifant is 1 mg/kg administered as an intravenous infusion over 1 hour, twice per week (every three to four days).
- Concomitant Dexamethasone: Gamifant is administered concomitantly with dexamethasone.
- For patients not receiving baseline dexamethasone: Begin dexamethasone at a daily dose of at least 5 to 10 mg/m² the day before Gamifant treatment begins.
- For patients already on dexamethasone: They may continue their regular dose, provided it is at least 5 mg/m².
- Dexamethasone can be tapered based on the treating physician’s judgment as the patient responds to Gamifant.
- Dose Modification Based on Response: The Gamifant dose can be titrated upward based on the patient’s clinical and laboratory response. Dose increases are considered if there’s an unsatisfactory improvement in clinical condition, which includes criteria such as persistent or recurrent fever, insufficient improvement in platelet count or neutrophil count, inadequate decrease in ferritin, or worsening splenomegaly or coagulopathy.
- Typical Dose Escalation: If response is unsatisfactory, the dose can be increased sequentially to 3 mg/kg (on Day 3), then to 6 mg/kg (from Day 6 onwards), and finally to a maximum of 10 mg/kg (from Day 9 onwards), if clinically indicated.
- Duration of Treatment: Gamifant is administered until hematopoietic stem cell transplantation (HSCT) is performed or until the patient no longer requires therapy for the treatment of HLH (i.e., complete or partial remission of HLH symptoms and normalization of laboratory markers). If HLH symptoms recur, Gamifant can be readministered.
- Preparation and Administration: Gamifant vials (available as 10 mg/2 mL, 50 mg/10 mL, and 100 mg/20 mL, all 5 mg/mL concentration, or higher concentrations like 50 mg/2 mL and 100 mg/4 mL as 25 mg/mL) are single-use only. The required amount is calculated based on patient weight and diluted with 0.9% Sodium Chloride Injection to a specific concentration range before intravenous infusion over 1 hour. It must not be mixed with other agents in the infusion bag or syringe.
Due to the critical nature of HLH, dosage adjustments and treatment duration are highly individualized and determined by a specialized medical team based on continuous monitoring of the patient’s complex clinical and laboratory parameters.
PRESCRIPTION
Gamifant (emapalumab-lzsg) is a highly restricted, prescription-only medication (POM). It is not available over-the-counter and its use is strictly controlled due to its specialized indication, potent mechanism of action, complex administration, and significant potential for serious side effects.
Key aspects of its prescription requirements include:
- Specialist Prescribing: Gamifant must be prescribed by a physician experienced in the diagnosis and treatment of primary hemophagocytic lymphohistiocytosis (HLH). This typically involves specialists such as hematologists, oncologists, or immunologists with expertise in rare inflammatory disorders.
- Confirmatory Diagnosis: Prescription requires confirmed diagnosis of primary HLH, often based on molecular diagnosis (gene mutations) or meeting a specific set of clinical and laboratory criteria (e.g., fever, splenomegaly, cytopenias, hypertriglyceridemia, hypofibrinogenemia, hemophagocytosis, low NK-cell activity, high ferritin, high soluble CD25). Secondary causes of HLH must be ruled out.
- Prior Authorization/Strict Criteria: Given its high cost and specific use, Gamifant often requires prior authorization from insurance providers and adherence to very strict medical necessity criteria set by health plans and regulatory bodies. This typically involves documentation of refractory, recurrent, or progressive disease, or intolerance to conventional HLH therapy.
- Pre-treatment Screening: Before initiation, extensive pre-treatment screening is required, including evaluation for infections (especially latent tuberculosis), as prophylactic treatment for certain infections may be necessary.
- Hospital/Clinic Administration: Gamifant is an intravenous infusion that must be prepared and administered by trained healthcare professionals in a hospital or specialized clinic setting. It cannot be self-administered at home.
- Patient Monitoring Requirements: Ongoing close monitoring of the patient’s clinical status, laboratory parameters, and potential adverse reactions is mandatory throughout the treatment course.
In summary, Gamifant’s prescription and use are limited to patients with a confirmed diagnosis of primary HLH under the strict supervision of specialized medical professionals.
FAQ's
What is Gamifant?
- Gamifant is a prescription biologic medication (monoclonal antibody) used to treat specific immune-mediated conditions.
What conditions is Gamifant used to treat?
- It is indicated for certain hyperinflammatory disorders — see prescribing information for exact FDA‑approved indications.
How does Gamifant work?
- It targets specific immune signaling pathways to reduce pathologic inflammation by neutralizing a key cytokine or receptor involved in immune activation.
How is Gamifant administered?
- Given by intravenous infusion per dosing schedule determined by the prescribing clinician and product labeling.
Who can receive Gamifant?
- Patients who meet clinical and diagnostic criteria for the approved indication(s) and for whom the drug is prescribed by a specialist.
What are common side effects of Gamifant?
- Infusion‑related reactions, increased infection risk, and other adverse events described in the product information.
Are there serious risks with Gamifant?
- Serious infections and hypersensitivity reactions are possible; monitoring per prescribing guidance is required.
Can Gamifant be used in children?
- Pediatric use depends on the approved indication and age/weight criteria in the prescribing information.
Is Gamifant safe during pregnancy or breastfeeding?
- Use in pregnancy or breastfeeding should be discussed with treating clinicians; balance risks and benefits and consult pregnancy/lactation data in the label.
Does Gamifant interact with other medications?
- Concomitant immunosuppressive therapies can increase infection risk; review all meds with the prescribing clinician.
How soon does Gamifant work?
- Onset of effect varies by condition and patient; some patients may show clinical improvement within days to weeks.
How long is Gamifant treatment continued?
- Duration depends on clinical response, indication, and treating specialist’s plan.
Is monitoring required while on Gamifant?
- Yes — baseline and periodic monitoring for infections, laboratory parameters, and infusion reactions per product guidance.
Can Gamifant increase my risk of infections?
- Yes — immune modulation can raise susceptibility to bacterial, viral, or opportunistic infections.
What should I do if I miss a dose?
- Contact the prescribing clinic or infusion center for instructions; do not self‑administer or restart without clinician guidance.
Are there vaccination considerations with Gamifant?
- Live vaccines are generally avoided during and for a period after immunosuppressive therapy; follow immunization guidance from the prescribing clinician.
Is Gamifant covered by insurance?
- Coverage varies; prior authorization and specialty pharmacy coordination are commonly required.
Where is Gamifant given?
- Typically administered in hospitals, infusion centers, or specialty clinics experienced with biologic infusions.
Can Gamifant be self‑administered at home?
- No — it is administered by healthcare professionals via IV infusion.
Where can I get more information or emergency help?
- Contact your prescribing clinician, specialty pharmacy, the drug manufacturer medical information line, or hospital emergency services for urgent reactions.
